En DE FR ES PL
Betaleikin - instructions for use, analogs, testimonials and release forms (injections in ampoules for injection of lyophilizate 0.05 μg, 0.5 μg and 1 μg) drugs for the treatment of blood infection, immunodeficiency, in adults, children and pregnancy. Composition

Betaleikin - instructions for use, analogs, testimonials and release forms (injections in ampoules for injection of lyophilizate 0.05 μg, 0.5 μg and 1 μg) drugs for the treatment of blood infection, immunodeficiency, in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Betaleukin. The reviews of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on Betaleikin use in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Betaleikin analogues in the presence of existing structural analogues. Use to treat blood, immunodeficiency, radiation sickness in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Betaleikin - stimulates hemopoiesis and early post-radiation recovery, has immunostimulating action and antiviral activity. The drug accelerates the recovery of stem potential and bone marrow hematopoiesis, especially granulopoiesis, after the damaging effects of cytostatics and ionizing radiation. This is due to his ability to initiate the entry of stem cells into the mitotic cycle and their mobilization into the blood, to increase the production of hematopoietic growth factors, to include mechanisms of general and local nonspecific resistance. Immunostimulating effect of the drug is realized by increasing the functional activity of neutrophilic granulocytes, induction of differentiation of precursors of immunocompetent cells, enhancing lymphocyte proliferation, activation of cytokine production and increasing antibody production. The drug has antiviral activity against hepatitis C virus due to direct action independent of interferon-alpha, using unique systems of activation of congenital antiviral immunity, induces the synthesis of endogenous interferon-alpha,and also promotes the abolition of the blocking effect of the hepatitis C virus on the biological activity of interferon-alpha.

 

Composition

 

Interleukin-1-beta + excipients.

 

Pharmacokinetics

 

After subcutaneous or intravenous administration, interleukin-1 beta is evenly distributed across all organs and tissues. It is excreted by the kidneys unchanged. Half-life with intravenous jet injection 7.5 minutes.

 

Indications

  • toxic leukopenia of the second and fourth degree, complicating chemo- and radiotherapy of malignant tumors, as a stimulant of leukopoiesis;
  • prophylaxis of leukopenia of the second and fourth degree during chemotherapy (with a peripheral blood leukocyte count of at least 3 × 109 per liter) as a protector of leukopoiesis;
  • secondary immunodeficiency states, developing after severe injuries, extensive surgical interventions, as a result of purulent-septic and purulent-destructive processes (including lung abscess, pleural empyema), infectious diseases, purulent rhinosinusitis with prolonged, recurrent and chronic course, chronic septic states;
  • acute radiation damage by accidental total and subtotal effects of ionizing radiation without complicated additional thermal exposure (dose, at an approximate estimate exceeds 1 Gy);
  • newly diagnosed pulmonary tuberculosis limited length with a predominance of productive type tissue reactions (with and without destruction) and pulmonary tuberculosis, in which the stored average dimensions productive foci in the lung tissue and the "residual space" on 4-5 month of treatment irrespective of the initial form of tuberculosis;
  • treatment of patients with chronic viral hepatitis C, genotype 1, in the absence of a virologic response to primary antiviral therapy with pegylated or standard interferons and ribavirin.

 

Forms of release

 

Injections in ampoules for injection lyophilizate 0.05 μg, 0.5 μg and 1 μg.

 

Instructions for use and dosing regimen

 

As leykopoeza stimulant drug is used in a dose of 0,015-0,020 mg per kilogram body weight, for immune stimulation in a dose of 0,005-0,008 mg per kilogram body weight. Treatment is carried out as a course of 5 daily intravenous drip infusions or subcutaneous injections.

 

To obtain an infusion solution for intravenous administration, the contents of the ampoule with the preparation immediately before administration are dissolved in 1 ml of a 0.9% solution of sodium chloride or water for injection and the total volume of the solution is brought to 100 ml with 0.9% sodium chloride solution. To achieve the estimated dose for infusions, this solution is diluted in the required amount (depending on the initial dose of the drug in the ampoule, correspondingly to its concentration in the solution obtained) in 500 ml of 0.9% sodium chloride solution or 5% Dextrose solution. Duration of infusion can vary from 120 to 180 minutes.

 

To obtain an injectable solution for subcutaneous administration, the contents of the ampoule with the drug are dissolved in 0.5-1 ml of a 0.9% solution of sodium chloride or water for injection.

 

If necessary, similar repeated courses of treatment can be conducted with an interval of two weeks.

 

Betaleukin as a means of emergency anti-radiation therapy is administered subcutaneously, within 2 hours after radiation exposure and a dose of 1 μg (the contents of the ampule are 1 μg diluted in 1 ml of 0.9% sodium chloride solution).

 

To treat tuberculosis, Betaleukin® is administered at a dose of 0.005 μg per kilogram of body weight.The drug is administered intravenously drip for 3 hours or subcutaneously. Solutions for infusions or injections are prepared in the manner described above. The treatment is carried out in a course cycle of 5 daily procedures.

 

Betaleukin is prescribed against the background of the use of anti-tuberculosis drugs, specific polychemotherapy is carried out by 4 drugs selected according to the drug sensitivity of the mycobacterium tuberculosis.

 

Complex antiviral therapy for patients with chronic viral hepatitis C, genotype 1, with no virologic response to pegylated or standard interferons and Ribavirin therapy, is supplemented with Beta leikin 0.5 μg (0.25 μg with a patient body weight less than 70 kg) subcutaneously 3 times a week (Monday, Wednesday, Friday), courses of 3 weeks, only 6 courses at intervals of 6 weeks. The total duration of antiviral therapy is 48 weeks.

 

Side effect

  • hyperemia (redness) and mild infiltration in the area of ​​administration;
  • chills;
  • malaise;
  • headache;
  • fatigue;
  • increase in body temperature to 37.5-39 degrees;
  • short-term exacerbation of suppuration with purulent rhinosinusitis;
  • allergic reactions of immediate type (anaphylaxis, urticaria, angioedema).

 

Contraindications

  • individual intolerance to the components of the drug;
  • septic shock;
  • severe fever above 38.5 ° C;
  • closed purulent foci (in particular in the absence and impossibility of draining the sinus);
  • allergic and autoimmune diseases;
  • pregnancy and lactation;
  • children and adolescence up to 18 years.

 

When using Betaleukin as a means of emergency anti-radiation therapy

  • combined radiation-thermal damage (KRTP);
  • febrile conditions above 37 ° C;
  • severe hypotension, blood pressure 90 to 60 and below;
  • shock of any etiology.

 

In the treatment of tuberculosis

  • the lesion volume of more than 3 segments (including including seeding centers) - the presence of destruction cavities more than 3 cm;
  • exudative tissue reaction in the lung tissue;
  • expressed symptoms of intoxication, including hyperthermia.

 

Application in pregnancy and lactation

 

Contraindicated in pregnancy and lactation.

 

Use in children

 

Contraindicated in children and adolescents under the age of 18 years.

 

special instructions

 

The use of the drug can shorten the duration of administration and the dose of antibiotics.

 

With purulent rhinosinusitis, local administration of Betaleukin is indicated to all patients receiving antibiotic therapy, even having anamnestic indications or confirmed allergic and autoimmune diseases. Such patients are shown sparing modes of administration:

  • in the form of local administration of the drug as a monotherapy;
  • on the background of antibiotic therapy;
  • step (single administration of the drug intravenously, in the following days only local application).

 

Impact on the ability to drive vehicles and manage mechanisms

 

Betaleukin does not affect the ability to drive a vehicle or potentially dangerous machinery.

 

Drug Interactions

 

Betaleukin should not be administered with any other drugs in one syringe to avoid interaction with the stabilizer and subsequent reduction in drug activity.

 

Inhibitors of cyclooxygenase (rheopyrin) relieve such effects of Betaleukin as, an increase in temperature and a reduction in the production of corticosteroids.

 

Steroid hormones reduce the pharmacological action of the drug Betaleukin.

 

Analogues of the drug Betaleukin

 

Structural analogs for the active substance:

  • Interleukin 1-beta.

 

Analogues on the pharmacological group (stimulators of hemopoiesis):

  • Irondekst;
  • Aranesp;
  • Argeferr;
  • Aeprin;
  • Binocrit;
  • Venofer;
  • Vero-epoetin;
  • Wialfer;
  • Vitamin B12;
  • Hemofer;
  • Granogen;
  • Granocyte;
  • Deoxynate;
  • Zarcio;
  • The Immigra;
  • CosmoFer;
  • Leukogen;
  • Leukomax;
  • To the Leichest;
  • Leucite;
  • Lonquex;
  • Maltofer;
  • Mamifol;
  • Methyluracil;
  • Myelastra;
  • Mircera;
  • Mozobail;
  • Monofer;
  • Neupogen;
  • Neuromax;
  • Neutrostim;
  • Neostimium;
  • Unstable;
  • Normosang;
  • Panagen;
  • Pentoxyl;
  • Polydane;
  • The Revolade;
  • Recormon;
  • Sorbitrim;
  • Tardiferon;
  • Tevagrastim;
  • Ferinzhekt;
  • Ferlatum;
  • Ferri;
  • Ferrinate;
  • Ferrograduum;
  • Ferronal;
  • Filgrastim;
  • Heferol;
  • Cyanocobalamin;
  • Cicomin;
  • Epokrin;
  • Epomax;
  • Eporati;
  • Epostim;
  • Epoetin;
  • Eprex;
  • Eralfon;
  • Erythropoietin.

 

Response of infectious diseases physician

 

Betaleukin is an effective drug for the stimulation of hematopoiesis. In addition, when administered, there is pronounced immunostimulating and antiviral activity. I assign it to patients with newly diagnosed lung tuberculosis.Betaleukin is also effective in chronic viral hepatitis C, when there is no virologic response to primary antiviral therapy with ribavirin, standard or pegylated interferons. The active substance interleukin-1-beta actively restores hematopoiesis processes in radiation sickness, chronic septic states, chronic leukopenia against the background of chemo- and radiotherapy of malignant tumors.

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions